New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 27, 2022 - The FDA approved Novartis’ Beovu (brolucizumab-dbll), for the treatment of diabetic macular edema (DME).
Download PDF
Return to publications
